Needham, United States
RES Group, Inc is an MIT spin-off specializing in mechanistic modeling & simulation services with a focus on accelerating R&D in drug development. Their expertise lies in Quantitative Systems Pharmacology (QSP) modeling, a field they have pioneered since 2001. The company offers a range of services, including First-in-Human (FIH) dose projections for IND applications and toxicity projections for regulatory submissions. With a successful track record of collaborating on over 100 new drug developments, RES Group has gained the trust of biotech and pharmaceutical companies.
They have had notable successes in the pharma industry, such as their Model Informed Drug Development (MIDD) approach for Takeda’s ultra-rare blood clotting disorder, resulting in the approval of ADZYNMA (ADAMTS13, recombinant-krhn) by the U.S. FDA. Additionally, RES Group's human dose projection was recently accepted in the IND clearance for treating Duchenne muscular dystrophy with Solid Biosciences' gene therapy candidate SGT-003.
With their impressive track record and specialization in a critical area of drug development, RES Group, Inc presents an intriguing investment opportunity for venture capitalists in the pharmaceutical and energy industries. Their innovative QSP modeling offers potential for impactful collaborations and advancements in drug development.